Psoriatic Arthritis Treat to Target vs. Usual Care (PRC-05-2011)

Pope Research

Status

Withdrawn

Conditions

Psoriatic Arthritis (PsA)

Treatments

Other: Intensive Care

Study type

Interventional

Funder types

Industry

Identifiers

NCT01692912

PRC-05-2011

Details and patient eligibility

About

Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score <2.6), or as per their routine care. The aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.

Full description

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Psoriatic Arthritis as diagnosed by a rheumatologist and meeting ACR classification criteria for PsA or CASPAR criteria
The subject must provide written informed consent for participation in the study before any study specific procedures are performed
Subject has 3 or more SJC on 28 joint count
Age >=18

Exclusion criteria

Subject has a history of being non-compliant
Serious concomitant illnesses that in the investigator's opinion negate ability to optimally treat the patient
If treating with TNF inhibitor, positive PPD > 5mm who have not received INH for recommended course or untreated TB (ie CXR evidence of latent infection). Usual screening is in place for standard of care.
Pregnancy, breast-feeding or considering pregnancy over the next 12 months